DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Friday. The firm set a “hold” rating on the stock.

Several other brokerages have also recently issued reports on DBVT. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright increased their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Trading Down 3.9 %

NASDAQ DBVT opened at $0.47 on Friday. The firm has a market cap of $45.26 million, a PE ratio of -0.52 and a beta of 0.66. DBV Technologies has a 1-year low of $0.44 and a 1-year high of $2.14. The stock has a 50-day moving average of $0.70 and a 200-day moving average of $0.85.

DBV Technologies’s stock is set to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.